Brokerages Set Immunome, Inc. (NASDAQ:IMNM) PT at $31.50

Shares of Immunome, Inc. (NASDAQ:IMNM) have earned a consensus rating of “Buy” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have covered the stock in the last year is $32.67.

Several research firms have commented on IMNM. Wedbush lifted their price target on Immunome from $27.00 to $33.00 and gave the company an “outperform” rating in a report on Monday, April 1st. Guggenheim initiated coverage on shares of Immunome in a research report on Monday, April 15th. They set a “buy” rating and a $35.00 target price for the company. Leerink Partnrs reissued an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. Finally, SVB Leerink initiated coverage on shares of Immunome in a research report on Monday, January 29th. They set an “outperform” rating and a $30.00 target price for the company.

Immunome Price Performance

IMNM opened at $15.48 on Monday. The stock has a market capitalization of $924.00 million, a price-to-earnings ratio of -2.87 and a beta of 1.66. The business has a 50-day moving average of $22.88 and a two-hundred day moving average of $14.87. Immunome has a 12 month low of $4.44 and a 12 month high of $30.96.

Institutional Trading of Immunome

A number of institutional investors and hedge funds have recently bought and sold shares of IMNM. Vanguard Group Inc. boosted its holdings in Immunome by 339.0% in the 4th quarter. Vanguard Group Inc. now owns 1,740,026 shares of the company’s stock worth $18,618,000 after acquiring an additional 1,343,697 shares during the period. Avidity Partners Management LP purchased a new position in Immunome in the 4th quarter worth approximately $14,268,000. Price T Rowe Associates Inc. MD boosted its holdings in Immunome by 505.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,051,222 shares of the company’s stock worth $11,249,000 after acquiring an additional 877,592 shares during the period. Point72 Asset Management L.P. purchased a new position in Immunome in the 2nd quarter worth approximately $3,307,000. Finally, TD Asset Management Inc purchased a new position in Immunome in the 3rd quarter worth approximately $1,063,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.